Glioblastoma: What the Survival Statistics Really Mean

Research-informed explainer — last updated April 12, 2026

A glioblastoma diagnosis is serious. The median survival is about 15 months with standard treatment — meaning half of patients live longer than that, and half live less. But a single median number can obscure what actually matters: who lives longer, what treatments have genuine evidence behind them, and what you can do to maximize your chances. This article will not soften that number, but it will explain what the research actually shows about survival, which treatments work, what molecular factors matter, and where hope is real versus where it is not yet.

This explainer draws on published research from five neuro-oncologists in the Convene directory. Patrick Wen, M.D., at Dana-Farber/Harvard, whose 4,216-cited NEJM review defined the current diagnostic and treatment framework for malignant gliomas, and whose laboratory led a landmark Phase Ib neoantigen vaccine trial [1][8][9]. Antonio Omuro, M.D., at Stanford, whose comprehensive JAMA review summarizes treatment standards and the current state of immunotherapy trials [2]. Karen Fink, M.D., Ph.D., at Baylor Scott and White, who is an investigator on the pivotal Phase 3 JAMA trial demonstrating that tumor-treating fields extend GBM survival [3][5]. Howard Fine, M.D., at Weill Cornell, whose foundational GBM stem cell biology work and bevacizumab Phase 2 trial shaped recurrence treatment [6][7][10]. Daniel Lachance, M.D., at Mayo Clinic, whose work on IDH, 1p/19q, and TERT promoter molecular groupings explains what tumor genetics mean for prognosis [4].

What glioblastoma is

Glioblastoma (GBM, also called WHO Grade 4 glioma or IDH-wildtype glioblastoma in the 2021 WHO classification) is the most common and most aggressive primary brain tumor in adults. It arises from glial cells and grows rapidly by infiltrating surrounding brain tissue rather than forming a clean boundary. This is why complete surgical removal is essentially impossible — even the most extensive surgery leaves microscopic tumor cells behind in the surrounding brain [1].

About 13,000 Americans are diagnosed with glioblastoma each year. Most have no identifiable hereditary risk factor. Diagnosis is confirmed by surgical biopsy with molecular profiling, which determines the subtype and has become as important as the pathology itself.

How it is diagnosed

The diagnostic pathway typically begins with neurological symptoms — seizures, headaches, personality changes, language problems, or weakness on one side of the body — followed by brain MRI showing a contrast-enhancing mass with surrounding edema. The imaging appearance is often strongly suggestive of GBM, but tissue is required for definitive diagnosis and molecular profiling.

The key molecular tests now performed on GBM tissue include:

• IDH mutation status: The single most important prognostic factor. IDH-wildtype GBMs (the large majority) are far more aggressive than IDH-mutant tumors. Patients with IDH-mutant Grade 4 gliomas have substantially longer median survival [4].
• MGMT promoter methylation: Methylation of the MGMT gene promoter silences a DNA repair enzyme, making the tumor more sensitive to temozolomide chemotherapy. Patients with MGMT-methylated tumors respond better to standard treatment and live longer.
• 1p/19q co-deletion: Relevant mainly to oligodendroglioma (a different but related tumor type), not classic GBM.
• TERT promoter mutations: Combined with IDH and 1p/19q status, help classify tumor groups with different prognoses [4].

Standard treatment

Current standard of care for newly diagnosed GBM in patients healthy enough to tolerate it follows the Stupp protocol from the pivotal 2005 Phase 3 trial: maximal safe surgical resection, followed by six weeks of concurrent radiation therapy and daily oral temozolomide, followed by six months of adjuvant temozolomide. This regimen improved median survival from 12.1 months (radiation alone) to 14.6 months. Patients with MGMT promoter methylation fared significantly better — median survival exceeded 20 months in that subgroup.

In 2017, a Phase 3 JAMA trial with 695 patients showed that adding tumor-treating fields (TTFields, delivered via a wearable device placed on the scalp) to maintenance temozolomide extended median overall survival to 20.9 months from 16 months in the temozolomide-alone arm. Patients compliant with the device for more than 90 percent of the time had a median survival of 24.9 months [3][5]. TTFields are now standard of care in the United States for newly diagnosed GBM, though not all centers or patients choose them.

For recurrent GBM, bevacizumab — an anti-VEGF antibody that blocks the tumor's blood supply — was studied in a Phase 2 trial of 48 patients and showed significant antitumor activity. Six-month progression-free survival was 42.6 percent in patients treated with bevacizumab alone, leading to accelerated FDA approval. However, bevacizumab has not extended overall survival in randomized trials for recurrent GBM, and it is used primarily to control symptoms and maintain quality of life at recurrence [7].

What "median survival" actually means

The median survival of about 15 months means half of patients with GBM live longer than this, and half live less. This number comes from population-level data across all patients of all ages and health statuses.

What moves an individual's prognosis toward the better half:

• Younger age: Patients under 50 consistently outperform older patients in trials. Patients under 40 sometimes achieve long-term survival.
• Good functional status (KPS score above 70): Patients who are active and independent at diagnosis fare substantially better than those who are already neurologically compromised.
• Extent of surgical resection: Gross total resection (removing as much visible tumor as possible) is associated with longer survival compared with partial resection or biopsy alone.
• MGMT methylation: One of the strongest molecular predictors. Methylated patients treated with temozolomide have median survivals in the 20 to 24 month range.
• Treatment at a high-volume center: Surgical expertise and access to clinical trials matter.

Long-term GBM survivors — patients alive at five years — do exist, though they represent roughly 5 percent of patients. Studies of these patients consistently show younger age, good functional status, gross total resection, MGMT methylation, and sometimes other favorable molecular features.

Immunotherapy and clinical trials

Immunotherapy has transformed several cancers but has not yet succeeded in GBM. The CheckMate 143 trial comparing nivolumab with bevacizumab in recurrent GBM found no survival benefit for nivolumab. The reasons are being actively studied — GBM has a uniquely immunosuppressive tumor microenvironment, and the blood-brain barrier complicates drug delivery.

Active research areas include neoantigen vaccines, which train the immune system to recognize the specific mutations in your tumor. A Phase Ib trial at Dana-Farber and other centers found that personalized neoantigen vaccines generated tumor-reactive T cells in the GBM tumor microenvironment — a promising early signal [8]. CAR-T cell therapy targeting GBM-specific antigens (EGFRvIII, IL13Ra2, GD2) is also in early trials.

Clinical trials are an important option at every stage of GBM — both at diagnosis (where adding an experimental agent to standard Stupp protocol may improve outcomes) and at recurrence (where standard options are more limited). Asking your neuro-oncologist about your eligibility for trials is a worthwhile conversation, not a last resort.

What to expect from treatment

Surgery is typically followed by six weeks of daily radiation appointments, usually Monday through Friday. Most patients can continue to live at home during this period. Fatigue is common; corticosteroids (typically dexamethasone) help manage brain swelling but can cause their own side effects including elevated blood sugar, mood changes, and muscle weakness. Temozolomide is taken orally and is generally better tolerated than older chemotherapy regimens, though nausea and fatigue are common.

MRI scans are obtained every two to three months to monitor treatment response and detect recurrence. The appearance of new enhancement on MRI can sometimes represent pseudoprogression — inflammation that looks like tumor growth but is actually a sign of treatment response. This is why changes in treatment are generally not made based on a single scan finding.

Neurological symptoms often fluctuate throughout treatment. Many patients are able to continue meaningful activities, work part-time, and maintain close relationships for substantial periods. Palliative care consultation early in the course of illness — not only at end-of-life — is associated with better quality of life and, in some data, with longer survival.

Questions to ask your doctor

• What are my tumor's molecular features — IDH status, MGMT methylation, TERT promoter status — and what do they mean for my prognosis and treatment response?
• Am I a candidate for gross total resection, and what functional deficits might surgery cause?
• Is tumor-treating fields (TTFields/Optune) recommended for me, and what does the daily usage commitment involve?
• Are there clinical trials I should consider at diagnosis, rather than waiting for recurrence?
• What is the plan for monitoring treatment response, and how will we distinguish pseudoprogression from true progression on MRI?
• When should I involve palliative care, and what does that actually mean in practice?

The bottom line

Glioblastoma is a genuinely serious diagnosis, and you deserve honest information. The median survival of about 15 months is real — but it is not your individual prediction. Younger age, good functional status, maximal safe resection, MGMT methylation, and treatment at a high-volume center all push outcomes toward the better half of that distribution. Standard treatment with surgery, radiation, temozolomide, and TTFields has a real evidence base. Bevacizumab helps at recurrence. Immunotherapy has not yet worked but remains under active investigation. Clinical trials exist at every stage and are worth exploring actively. The goal is not to minimize what you are facing — it is to make sure you have the information you need to pursue every legitimate option.